Childhood cancer treatment has increasingly achieved favorable long-term survival rates, shifting focus toward reducing long-term comorbidities.
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue tumor, and radiation therapy is essential for its treatment.
Proton beam therapy (PBT) is currently utilized due to its potential to reduce long-term complications; however, data on its impact on tumor prognosis remain limited.
